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Abstract
Quorum sensing controls the expression of a wide range of important traits in the opportunistic pathogen Pseudomonas
aeruginosa, including the expression of virulence genes and its CRISPR-cas immune system, which protects from
bacteriophage (phage) infection. This finding has led to the speculation that synthetic quorum sensing inhibitors could be
used to limit the evolution of CRISPR immunity during phage therapy. Here we use experimental evolution to explore if and
how a quorum sensing inhibitor influences the population and evolutionary dynamics of P. aeruginosa upon phage DMS3vir
infection. We find that chemical inhibition of quorum sensing decreases phage adsorption rates due to downregulation of the
Type IV pilus, which causes delayed lysis of bacterial cultures and favours the evolution of CRISPR immunity. Our data
therefore suggest that inhibiting quorum sensing may reduce rather than improve the therapeutic efficacy of pilus-specific
phage, and this is likely a general feature when phage receptors are positively regulated by quorum sensing.
Introduction
The increase in antimicrobial resistance has led to a
resurgence of interest in phage therapy, where bacterial
viruses (phage) are used to treat bacterial infections [1–4].
Pseudomonas aeruginosa is an important source of
nosocomial infections and potential target for phage
therapy [5]. In the laboratory, bacteria tend to rapidly
evolve resistance to phage [6], which in a clinical setting
might limit the efficacy of the therapeutic phage appli-
cation [2]. Rapid phage resistance evolution is often due
to cell surface alterations that interfere with phage
adsorption, or the acquisition of CRISPR-based immu-
nity, where bacteria insert phage-derived sequences into
CRISPR loci on the host genome, which are used to detect
and destroy the same or closely related phage during
future infections [7–10]. In the case of P. aeruginosa
PA14, both these mechanisms of phage resistance have
been shown to evolve at high frequencies in the labora-
tory, but the dominant mechanism depends on environ-
mental variables, such as the microbial community
context in which infections occur [11], the level of phage
genetic variation [12], and the force of infection [13, 14].
The force of infection is an important determinant of
CRISPR immunity evolution because unlike surface-
based resistance, which carries a fixed fitness cost,
CRISPR immunity is associated with an infection-induced
fitness cost due to the expression of phage genes prior to
clearance of the infection [14, 15]. Hence, in environ-
ments with a high force of infection, surface-based
resistance is favoured over CRISPR immunity and vice
versa. Because evolution of surface-based resistance, but
not CRISPR immunity, is associated with virulence trade-
offs [11], being able to manipulate which type of phage
resistance evolves and limiting overall resistance devel-
opment could have important clinical impacts.
It was recently demonstrated that Quorum Sensing (QS)
controls expression of the CRISPR-cas immune system in
P. aeruginosa [16] and in Serratia [17]. Based on these
findings it was suggested that chemical QS inhibitors could
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be leveraged to limit the evolution of CRISPR-based
immunity in a clinical setting [16]. QS is a well-studied
bacterial communication system which allows bacteria to
monitor local cell densities based on the concentration of
small autoinducer molecules (AIs). P. aeruginosa PA14
encodes several QS systems, including two that use acyl
homoserine lactone (AHL) signalling (LasIR and RhlIR),
and the PQS system (for Pseudomonas quinolone signal)
(reviewed in [18]). The AHL-based QS systems are
involved in regulation of around 6% of the genes encoded
by P. aeruginosa [19–21], including CRISPR-cas [16] as
well as genes involved in virulence and biofilm formation
[22]. The LasIR and RhlIR systems are organised in a
hierarchical manner with LasIR at the top of the hierarchy
[23, 24]. LasI produces the AHL signal molecule 3-oxo-
C12-homoserine lactone (3OC12-HSL), which is released
from the cell from where it diffuses until it is taken up by
the same or other bacteria in the environment. As cell
densities increase, the concentration of the 3OC12-HSL
autoinducer within cells increase, which is sensed through
the LasR receptor. Beyond a threshold in the 3OC12-HSL
concentration, LasR-3OC12-HSL complexes activate target
genes, including both LasI and RhlIR. RhlI produces the
AHL signal molecule C4-homoserine lactone (C4-HSL).
This autoinducer is detected by the RhlR receptor, leading
to activation of a second wave of QS genes [25, 26]
(reviewed in [27, 28]).
Because LasIR and RhlIR QS systems control such a
broad range of genes, it remains difficult to predict how
QS inhibitors impact phage therapy. For example, these
QS systems of P. aeruginosa activate not only expression
of the CRISPR-cas immune system [16] but also that of
its Type IV pili [29], which serve as receptors for many
Pseudomonas phage [29–34]. Manipulation of QS may
therefore affect both the resistance levels of the host and
the infectivity levels of the phage that require type IV pili
for infection. Since it remains unclear what the overall
effect of QS inhibitors is on the efficacy of phage therapy,
we measured how chemical inhibition of QS using Bai-
calein [35] impacts the ecological and evolutionary
interaction between P. aeruginosa PA14 and its pilus-
specific phage DMS3vir under in vitro laboratory condi-
tions. Our data show that QS inhibition triggers pheno-
typic changes in the bacterial population that result in
partial immunity to phage due to reduced adsorption to the
host cells, and the resulting decrease in phage infection
frequencies favours the evolution of CRISPR immunity
over surface-based resistance. These data suggest that
inhibition of QS can reduce the efficacy of phage therapy
in a clinical context when QS inhibition results in reduced
expression of the phage receptor resulting in less frequent
successful infections.
Methods
Bacterial strains and phage
We used P. aeruginosa UCBPP-PA14 (referred to as WT), P.
aeruginosa UCBPP-PA14 cas7::LacZ (referred to as
CRISPR-KO, since it carries a non-functional CRISPR-cas
system) [36], a previously described CRISPR-KO-derived
surface mutant (referred to as sm) [14], and P. aeruginosa Tn::
pilA (referred to as pilA KO) [37], a CRISPR-cas immune
isolate of P. aeruginosa UCBPP-PA14 possessing two spacers
targeting the phage DMS3vir (referred to as BIM2 – Bacter-
iophage insensitive Mutant, previously described in [14]), as
well as a double synthase mutant strain of P. aeruginosa
UCBPP-PA14, ΔlasI ΔrhlI, (referred to as QS mutant) [16].
Cultures were started from a stock stored at −80 oC and were
grown in M9 media at 37 oC for 3 days with transfers to fresh
media each day to allow acclimatisation. For all infection
experiments we used the previously described mu-like phage,
DMS3vir [36]. We also used DMS3vir-acrIF1 described in
[38], which carries the anti-CRISPR gene acrIF1 that effec-
tively blocks the CRISPR-cas immune systems of P. aerugi-
nosa PA14 [38–40] during streak assays to determine the
mechanistic basis of phage resistance. Full datasets for all
experiments are available at: https://datadryad.org/stash/share/
Tt20sh0vKBz6gkoqKWHkzkSYMUdFj0qMBEiq1tUdAoo.
Evolution experiments
Infection experiments were carried out in glass vials
containing 6 ml of M9 media with 0.2% glucose
supplemented with 100 µM Baicalein (Cayman Chemical)
dissolved in DMSO, and 106 cfu/ml P. aeruginosa
WT. The same experiment was carried out concurrently
with the QS mutant in the presence or absence of 2 µM
3OC12-HSL and 10 µM C4-HSL (Sigma) dissolved
in DMSO. Control treatments received the same amount
of DMSO. Total amounts of 104 plaque forming units
(pfu) (low phage), 107 pfu (mid phage) or 109 pfu
(high phage) were added at the same time as the
bacteria. Microcosms were incubated at 37 °C while
shaking at 180 rpm. Every 24 h microcosms were sampled
and transferred to fresh media at a 1:100 dilution.
Samples from the infected cultures were taken prior to
each transfer and chloroform treated to kill bacteria as
described previously [38]. 5 µl of a serial dilution of
chloroform treated sample was spotted onto a lawn of
sensitive bacteria (CRISPR-KO strain). Plaques were
counted and densities were calculated as pfu/ml. Bacteria
were sampled at 3 days post infection to analyse the
resistance mechanisms that evolved in response to phage
infection.
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Resistance mechanism analysis
To determine whether bacteria had evolved phage resis-
tance, and whether this was surface-based resistance or
CRISPR-based immunity, we performed cross-streak assays
as described previously [14]. Briefly, bacterial colonies
were isolated by plating on LB agar, 24 colonies per
replicate were picked at random per replicate, grown
overnight in M9 media supplemented with 0.2% glucose
and then streaked across the ancestral phage (DMS3vir) and
the phage carrying the anti-CRISPR gene (DMS3vir-
acrIF1) [38]. Colonies which were resistant to the ances-
tral phage but not the phage carrying an anti-CRISPR gene
were classed as CRISPR immune, whereas colonies that
were resistant against both DMS3vir and DMS3vir-acrIF1
were classed as having sm (surface mutation) resistance.
Colonies that were not resistant to either phage were classed
as sensitive. Results were confirmed with PCR of both of
the CRISPR loci which P. aeruginosa possesses to check
for spacer acquisition in WT and QS mutant clones as
described previously [14].
Phage adsorption
WT P. aeruginosa was grown for 24 h in media supple-
mented with either DMSO (control) or the QS inhibitor.
Cultures were centrifuged at 3500 rpm to form a pellet.
The supernatant was discarded and the pellets were
resuspended in 5 ml of pre-heated (37 oC) medium with or
without the QS inhibitor to OD600 0.2. Cultures were
incubated at 37 oC, 180 rpm for 3 h to achieve mid-log
phase and then diluted with pre-heated growth medium to
a final volume of 15 ml. 6 ml of each sample was taken
and stored on ice to be used to quantify bacterial density
at the start of the experiment, as described below. The
remaining 9 ml was put back in the incubator at 37 oC,
180 rpm. One tube of plain growth media was also pro-
cessed as a control. Cultures were incubated for 5 min to
allow for temperature equilibration. 1 ml of pre-warmed
phage in growth media was added to each culture with a
final concentration of 2 × 105 pfu/ml. Cultures were
mixed and a sample taken and added to Eppendorf vials
containing 100 µl of chloroform, vortexed and stored on
ice. This process was repeated at 3, 6, 9, 12, 15, 20, 25,
30, 40 and 50 min post infection. Phage densities were
calculated by spotting virus samples isolated by chloro-
form extraction on a lawn of CRISPR KO bacteria.
Bacterial densities were determined by plating dilutions
of the original cultures, which were taken at the start of
the experiment and stored on ice, on LB Agar plates and
counting CFUs. The fraction of free phage particles at
each time point were calculated relative to the phage
titre at T0.
Phage elimination assays
To measure CRISPR-mediated phage elimination over
longer timespans, we mixed the Bacteriophage Insensitive
Mutant BIM2, which possesses 2 spacers targeting
DMS3vir in its’ CRISPR array with DMS3vir in glass
microcosms containing 6 ml of M9 media supplemented
with 0.2% glucose or DMSO with or without a QS inhibitor
(100 µM Baicalein) or AIs (2 µM 3OC12-HSL+ 10 µM C4-
HSL) and inoculated with 106 cfu/ml of the BIM. Cells
were then infected with 106 pfu/ml of phage DMS3vir.
Vials were incubated at 37 °C while shaking at 180 rpm for
24 h and then sampled. Phage titres were determined via
chloroform extraction and spot assay, as described above.
Competition experiments
We measured fitness by competing the BIM2 targeting
DMS3vir against either the phage-sensitive CRISPR-KO
strain or against the phage-resistant surface mutant (the pilA
KO or sm strain). A CRISPR immune strain with 2 phage-
targeting spacers was used to avoid confounding effects from
the evolution of “escape phage” that carry mutations in their
target sequences [38, 41]. Competitions were performed in
glass microcosms containing 6ml of M9 media with 0.2%
glucose, and containing either the inhibitor (100 µM Baica-
lein), the autoinducers (2 µM 3OC12-HSL+ 10 µM
C4-HSL), or both the QS inhibitor and inducers at these same
concentrations. Controls contained the same volume of
DMSO only. Microcosms were then inoculated with 106
colony forming units (cfu)/ml of a 1:1 mix of the competing
strains. Cells were infected with 106 pfu/ml of phage
DMS3vir. Vials were incubated at 37 °C while shaking at
180 rpm for 24 h and then sampled. The relative frequencies
of each strain were determined via serial dilution and plating
on 1.5% LB agar plates containing 50mg/ml X-gal (5-bromo-
4-chloro-3-indolyl-β-D-galactopyranoside). In each competi-
tion experiment one of the competing treatments carried the
LacZ gene which produces the enzyme β-galactosidase,
causing colonies to turn blue when grown on media con-
taining X-gal. This allowed us to visually distinguish com-
peting clones for quantification of their relative frequencies.
Relative fitness was calculated as rel. fitness= [(fraction
strain A at t= x) * (1 – (fraction stain A at t= 0))] / [(fraction
strain A at t= 0) * (1 – (fraction strain A at t= x)]).
Motility assays
P. aeruginosa WT or the QS mutant were streaked onto
1.5% LB agar plates and grown overnight at 37 oC. In total,
6 ml M9 media was supplemented with 0.2% glucose and
was inoculated with either the WT or QS mutant and grown
for 24 h at 37 oC, while shaking at 180 rpm. Swimming
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ability was determined by inserting a pipette tip containing
WT bacteria or the QS mutant halfway through a 0.3% LB
agar plate. Swarming assays were performed by spotting
5 µl of undiluted liquid culture onto a 0.5% LB agar plate.
All motility assay plates were incubated for 24 h at 37 oC.
Motility was measured as the diameter of bacterial growth
in mm at the widest point which intersected the point of
inoculation.
Results
The effect of QS inhibition on phage resistance
evolution
To measure whether chemical QS inhibitors can indeed be
used to limit the evolution of CRISPR-based immunity
against a pilus-specific phage, we exposed WT PA14 to
either 104, 107 or 109 pfu of phage DMS3vir in the presence
or absence of Baicalein, a potent QS inhibitor [35] (Fig. 1).
In our control, (WT supplemented with DMSO) evolu-
tion of CRISPR-based immunity decreased (and surface-
based resistance (sm) increased) with increasing phage titre,
as reported previously [11, 13, 14], with almost all bacteria
having evolved CRISPR immunity in the low phage treat-
ment compared to around three quarters of the population in
the mid and high phage treatments (Fig. 1). However, when
QS inhibitors were added, we observed changes in the
patterns of phage resistance evolution that were contrary to
our expectation of a general reduction in CRISPR-mediated
immunity. Specifically, in the presence of a QS inhibitor
there was a significant increase in the persistence of
phage-sensitive bacteria during infection with 104 pfu
(Mann–Whitney U= 3, p < 0.05) or 107 pfu (U= 1, p <
0.01) of DMS3vir. Inhibition of QS was also associated
with a reduction in the evolution of CRISPR immunity
upon infection with 104 pfu of phage (U= 0, p < 0.01), or a
reduction in sm resistance upon infection with 107 pfu of
phage (U= 0, p < 0.01). The persistence of sensitive bac-
teria in QS inhibitor treatments was no longer observed
when bacteria were infected with 109 pfu of phage
DMS3vir. Under those conditions, levels of CRISPR
immunity were slightly higher compared to the control, and
levels of sm resistance were slightly reduced.
The effect of QS inhibition on phage receptor
expression
We envisaged two possible reasons why in the presence of
Baicalein the evolution of phage resistance might be
reduced upon infection with 104 or 107 pfu of DMS3vir.
First, it may be the case that phage amplification is less
efficient in the presence of the QS inhibitor, resulting in
weaker selection for resistance. Second, QS inhibition may
Fig. 1 Inhibiting QS results in reduced phage sensitivity and
prolonged phage persistence at low phage densities. Observed
resistance mechanism evolution in P. aeruginosa PA14 WT or surface
mutant (sm) supplemented with DMSO (dark grey bars/points) or
100 µM QS inhibitor Baicalein (light grey bars/points) and at 3 days
post infection with (A) 104 pfu (B) 107 pfu (C) 109 pfu of phage
DMS3vir. Bars represent mean proportions of each of the different
bacterial phenotypes (i.e., the proportion of bacteria in the population
that evolved CRISPR immunity, acquired surface mutations or that
remained sensitive), error bars indicate 95% confidence interval, points
represent individual replicates, N= 6.
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cause cells to downregulate the phage receptors, if these are
also regulated by QS [42, 43], which would cause them to
become more resistant to phage infection. Indeed, the Type
IV Pilus (T4P), which is the receptor of many Pseudomonas
phage including DMS3vir [29–34, 44], is known to be
regulated by QS, and manipulation of QS can therefore
affect phage sensitivity [29]. To test the first hypothesis, we
monitored the phage densities throughout the evolution
experiment described above. This showed that in the pre-
sence of the QS inhibitor, phage amplification was higher
than or equal to that observed in the control (Fig. S1).
Reduced phage amplification can therefore not explain the
results of this experiment.
To test the second hypothesis, that phage receptor
expression is affected by QS inhibition, we measured the
impact of Baicalein on P. aeruginosa PA14 swarming
motility, a QS-regulated group behaviour which requires
T4P and flagella activity [45–48]. This analysis showed that
the lasI rhlI QS mutant was less able to swarm compared to
WT cells (p < 0.0001) and that WT cells grown in the
presence of the QS inhibitor Baicalein were no different in
swarming ability to that of the QS mutants (p > 0.9) (Fig.
S2A). As a control, we also measured swimming motility of
the WT strain, which is known to be an individual beha-
viour driven only by flagella activity [49]. As expected,
there was no significant effect of Baicalein on swimming
motility in the WT and the lasI rhlI QS mutant strains (p >
0.1 in all cases) (Fig. S2B). Collectively, these data there-
fore confirm that QS inhibition using Baicalein inhibits a
QS-controlled T4P-dependent group behaviour in PA14.
The effect of QS inhibition on phage adsorption
Next, to investigate how these phenotypic changes induced
by the presence of baicalein affect the infectivity of phage
DMS3vir, we measured whether Baicalein affects phage
adsorption. To this end, we infected WT P. aeruginosa
PA14 cells in exponential growth phase with phage
DMS3vir at a multiplicity of infection of 0.01 and measured
phage titres over 50 min in the presence or absence of Bai-
calein (Fig. 2A). This revealed that phage took significantly
longer to adsorb to host cells when the QS inhibitor was
added to the media (Welch’s t test T= 2.548, DF= 13.78,
p < 0.05) supporting the hypothesis that QS inhibition leads
to a reduction in the rate of phage DMS3vir adsorption.
Previous work has shown that CRISPR immune bacteria
cause a decline in phage densities because of their ability to
continually remove phage from the population [38, 50],
However only phage that adsorb to the bacterial cell and
inject their genome will be targeted and removed via
CRISPR-Cas activity. We therefore hypothesized that the
decrease in phage adsorption observed when baicalein was
present would result in higher phage titres. To test this
hypothesis we infected CRISPR immune bacteria with
109 pfu of DMS3vir in the presence or absence of Baicalein
or synthetic autoinducers and measured phage titres after
24 h of infection (Fig. 2B). This showed that phage titres
were only slightly above the threshold of detection after
24 h of infection in the control treatments. However, there
was a significant decrease in the amount of phage that had
been removed by CRISPR immune bacteria in the presence
Fig. 2 Phage are less able to infect hosts when QS is inhibited.
A Phage adsorption over time (3–50 min) when WT P. aeruginosa is
infected with phage when supplemented with DMSO (control) (dark
grey line) or 100 µM QS inhibitor Baicalein (light grey line). Samples
were taken at 3, 6, 9, 12, 15, 20, 25, 30, 40 and 50 min post infection.
Lines represent mean % of free phage particles detected, N= 3 (B)
Titre of phage remaining at 24hpi of a CRISPR resistant host pos-
sessing two unique spacers targeting the infecting phage (BIM2) when
initially infected with 109 phage. Bars represent mean titre of phage
present at 24hpi, error bars indicate 95% confidence interval, points
represent individual replicates, N= 6, Y axis is log10 scale.
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of the QS inhibitor (Mann–Whitney U= 0, p < 0.01) or the
inhibitor and AIs combined (U= 0, p < 0.01). This is con-
sistent with the reduction in phage adsorption in the pre-
sence of the QS inhibitors (Fig. 2A), since this leads to
fewer infections and therefore a reduction in phage removal
by CRISPR immune bacteria.
The fitness effects of QS inhibition for immune,
resistant and sensitive bacteria
Collectively, these data led us to predict that applying
Baicalein may reduce the efficacy of phage-mediated killing
by enhancing the intrinsic levels of phage resistance of the
bacteria. To test this, we measured how Baicalein affects the
fitness of phage sensitive bacteria in the presence of phage,
by competing sensitive bacteria lacking a functional
CRISPR-cas immune system (CRISPR KO strain) against a
pilus deletion mutant (a PilA KO strain) that lacks the T4P
and is fully resistant to phage DMS3vir. This showed that
sensitive bacteria were always outcompeted by the pilus
deletion strain in the presence of phage, as expected.
However, sensitive bacteria had a significantly higher fit-
ness when Baicalein was added to those competition
experiments (Mann–Whitney U= 0, p < 0.005) (Fig. 3A).
These data therefore confirm that Baicalein increases the
resistance levels of bacteria against pilus-specific phage,
hence lowering the infectivity of the phage and potentially
the efficacy of phage therapy cocktails containing baicalein.
We speculated that the reduced phage adsorption in the
presence of Baicalein may also explain the high levels of
CRISPR immunity and low levels of sm resistance that
evolve under the highest phage exposure levels (Fig. 1).
CRISPR immunity is associated with an infection-induced
fitness cost, whereas sm is associated with a fixed cost [14].
As a consequence, inhibition of QS and phage adsorption
could lead to an enhanced fitness of CRISPR immune
bacteria relative to surface mutants. Indeed, direct compe-
tition between a CRISPR immune clone (BIM2) and a
bacterium with surface-based resistance (sm) revealed that
the relative fitness of BIM2 increased in the presence of
Baicalein (Mann–Whitney U= 0, p < 0.005), and was not
affected by the addition of AIs (U= 17, p > 0.9) (Fig. 3B).
Both the sm strain and BIM2 possess complete immunity
against the infecting phage (no plaques observed). While
the sm strain has a slightly higher fitness during phage
infection in the absence of QS manipulation, the relative
fitness of BIM2 is higher than that of the sm strain when QS
is inhibited. The increased fitness of CRISPR immune
bacteria further supports the idea that they are infected at a
lower frequency when QS is inhibited.
Finally, given that CRISPR immune bacteria are less
efficient in removing phage in the presence of Baicalein
(Fig. 2), and sensitive bacteria will be affected by the pre-
sence of the phage more strongly than CRISPR immune
bacteria, we hypothesized the outcome of direct competition
between CRISPR immune bacteria and sensitive bacteria is
likely to be also affected by Baicalein. Direct competition
between CRISPR immune bacteria and sensitive bacteria
showed that CRISPR immune bacteria outcompete sensitive
bacteria in the presence of phage, as expected. Crucially, the
fitness of CRISPR immune bacteria relative to sensitive
bacteria increased in the presence of Baicalein (U= 2, p <
Fig. 3 Inhibiting QS increases the fitness of P. aeruginosa in the
presence of 106 pfu of phage. A Relative fitness of sensitive CRISPR-
KO strain during competition with the phage resistant surface mutant
(sm). B Relative fitness of BIM2 during competition with a phage
resistant surface mutant (sm). C Relative fitness of BIM2 during
competition with a sensitive CRISPR-KO strain. Box plots show the
median, 25th and 75th percentile, and the interquartile range. Raw
values from each replicate are shown as points, N= 6. Dotted line in
panels (B and C) indicates the point at which competing strains are
equally fit (when relative fitness = 1).
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0.05) (Fig. 3C). By contrast, the addition of synthetic AIs
had no significant impact on the relative fitness of the
CRISPR immune bacteria (Mann–Whitney U= 11, p >
0.9), which suggests that QS systems may already be
saturated under the conditions used here.
Discussion
P. aeruginosa is one of the leading pathogens responsible
for nosocomial infections and the most important pathogen
associated with chronic airway infections in cystic fibrosis
patients [51]. The rapid increase in antimicrobial resistance
has led to many P. aeruginosa infections being very diffi-
cult to eradicate [52]. Phage therapy is therefore considered
a viable alternative or complementary treatment of P. aer-
uginosa infections, and some experimental studies and
clinical case studies have shown promising results [53].
However, evolution of phage resistance may limit the long-
term effectiveness of phage-based therapeutics. One way to
limit the evolution of phage resistance by P. aeruginosa is
by using cocktails of different phages that use different
receptors, since in this case multiple mutations in different
receptor genes are needed to resist all phages [54]. When
bacteria encode a CRISPR-Cas immune system, as is the
case for approximately half of all sequenced P. aeruginosa
isolates [55], this strategy may become less effective, since
bacteria can in principle pick up multiple spacers that target
the different phage in the cocktail [56–59]. Being able to
limit the evolution of CRISPR immunity could have
important clinical impact, since bacteria that remain phage
sensitive or evolve CRISPR immunity are more likely to
retain their virulence levels compared to bacteria that evolve
surface-based resistance [11, 60, 61].
In the experiments presented here we tested the
hypothesis that, because QS regulates CRISPR-cas
expression [16, 62], chemical inhibition of QS might
enhance the efficacy of phage-mediated killing of bacteria
and steer evolution of phage resistance away from CRISPR
immunity and towards surface-based resistance. However,
in contrast to the predicted synergy between Baicalein and
phage, we found that these compounds have antagonistic
effects. Specifically, we found that Baicalein increased
survival of sensitive bacteria and increased the fitness of
sensitive and CRISPR immune bacteria relative to surface
mutants. This is because QS also regulates expression of the
T4P [29], which is used as a receptor by many Pseudo-
monas phage, including phage DMS3vir [44]. As a con-
sequence, the rate of phage adsorption is reduced in the
presence of Baicalein, which favours CRISPR immune
bacteria over surface mutants likely because of their
induced and fixed costs of resistance, respectively [14]. This
shows that QS inhibition may have unanticipated effects on
the evolutionary outcome of bacteria-phage interactions.
Such antagonistic effects are expected when host factors
that are important for phage infection and/or replication are
positively regulated by QS, whereas synergistic interactions
between QS inhibitors and phage are more likely when QS
downregulates the expression of phage receptors. Experi-
mental studies with Escherichia coli have demonstrated QS-
mediated downregulation of receptors used by its phage
Lambda and Chi at high cell densities [43] and similar
findings were reported for Vibrio anguillarium, which was
more resistant to infection by its phage KVP40 at high cell
densities due to QS-mediated downregulation of the phage
receptor OmpK [42]. In the case of P. aeruginosa, the vast
majority of phage characterized to date appear to either use
lipopolysaccharides or the T4P as their receptor [33]. While
this work shows that synergy is unlikely between pilus-
specific phage and QS inhibitors, synergy between Baica-
lein and LPS-specific phage remains an exciting possibility
that awaits experimental examination in future studies.
Manipulation of bacterial QS may also directly impact
phage infection dynamics (i.e., independent of changes in host
gene expression). Some temperate phage carry QS receptors
[63] that can bind the autoinducers produced by the host they
infect [64]. A prophage of Vibrio cholera that carries the QS
receptor VqmA uses the autoinducers produced by the host as
a cue for prophage induction when cell densities of the host
are high [65]. Other temperate phage encode their own QS
systems, known as Arbitrium systems, and preferentially enter
the prophage state once the signal concentration becomes
high, presumably because this indicates that available hosts
are running out [66]. These examples highlight the impor-
tance of QS in shaping the epidemiology of phage, and
manipulation of QS could conceivably alter infection
dynamics and the mobility of some phage within microbial
communities, which could have important implications for the
bacterial population dynamics.
In summary, QS inhibitors offer exciting opportunities to
manipulate the expression of genes that underpin phage
resistance and clinically important traits and group beha-
viours such as the expression of virulence determinants
[67], toxin production [68], biofilm formation [69], and
swarming motility [45]. Because of the many phenotypes
controlled by QS, the phenotypic, population dynamics and
evolutionary consequences of QS inhibitors are difficult to
predict, and experimental tests in laboratory settings and
more ecologically relevant infection models will be critical
to understand if and how these chemicals can be used in a
clinical context and in combination with which phage.
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